MA56466A - Anticorps anti-epha4 - Google Patents

Anticorps anti-epha4

Info

Publication number
MA56466A
MA56466A MA056466A MA56466A MA56466A MA 56466 A MA56466 A MA 56466A MA 056466 A MA056466 A MA 056466A MA 56466 A MA56466 A MA 56466A MA 56466 A MA56466 A MA 56466A
Authority
MA
Morocco
Prior art keywords
epha4 antibodies
epha4
antibodies
Prior art date
Application number
MA056466A
Other languages
English (en)
Other versions
MA56466B1 (fr
Inventor
Maki Deguchi
Toshio Imai
Eiji Inoue
Tomomi Kawakatsu
Aki Nakatani
Akio Yamada
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA56466A publication Critical patent/MA56466A/fr
Publication of MA56466B1 publication Critical patent/MA56466B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA56466A 2019-07-01 2020-06-29 Anticorps anti-epha4 MA56466B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019122982 2019-07-01
PCT/JP2020/025465 WO2021002312A1 (fr) 2019-07-01 2020-06-29 ANTICORPS ANTI-EphA4
EP20834769.0A EP3995582B1 (fr) 2019-07-01 2020-06-29 Anticorps anti-epha4

Publications (2)

Publication Number Publication Date
MA56466A true MA56466A (fr) 2022-05-11
MA56466B1 MA56466B1 (fr) 2026-07-31

Family

ID=74066003

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56466A MA56466B1 (fr) 2019-07-01 2020-06-29 Anticorps anti-epha4

Country Status (29)

Country Link
US (2) US10947313B2 (fr)
EP (1) EP3995582B1 (fr)
JP (2) JP6979147B2 (fr)
KR (1) KR102953475B1 (fr)
CN (2) CN113906050B (fr)
AR (1) AR119303A1 (fr)
AU (1) AU2020300205B2 (fr)
BR (1) BR112021025161A2 (fr)
CA (1) CA3139398A1 (fr)
CL (1) CL2021003326A1 (fr)
CO (1) CO2021016588A2 (fr)
ES (1) ES3073217T3 (fr)
FI (1) FI3995582T3 (fr)
IL (1) IL287828A (fr)
JO (1) JOP20210333A1 (fr)
LT (1) LT3995582T (fr)
MA (1) MA56466B1 (fr)
MX (1) MX2021015298A (fr)
MY (1) MY207780A (fr)
PE (1) PE20220570A1 (fr)
PH (1) PH12021553090A1 (fr)
PT (1) PT3995582T (fr)
RS (1) RS68231B1 (fr)
SG (1) SG11202112433VA (fr)
SM (1) SMT202600263T1 (fr)
TW (3) TWI866304B (fr)
UA (1) UA129772C2 (fr)
WO (1) WO2021002312A1 (fr)
ZA (1) ZA202108836B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
EP3995582B1 (fr) 2019-07-01 2026-04-22 Eisai R&D Management Co., Ltd. Anticorps anti-epha4
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US20240010735A1 (en) * 2020-12-24 2024-01-11 Eisai R&D Management Co., Ltd. Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis
CN118234864A (zh) * 2021-11-11 2024-06-21 卫材R&D管理有限公司 抗EphA4抗体
WO2025151607A1 (fr) * 2024-01-10 2025-07-17 Santa Ana Bio, Inc. Méthodes et compositions pour le traitement de maladies auto-immunes, allergiques et inflammatoires

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1094731A (en) 1911-06-06 1914-04-28 Lucien Linden Oxidizing process.
JP2824433B2 (ja) 1988-12-09 1998-11-11 財団法人化学及血清療法研究所 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター
CA1339413C (fr) 1988-06-24 1997-09-02 Junichi Miyazaki Vecteur pour l'expression d'un gene exogene, renfermant un promoteur de gene .beta.-actine de poule
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5902732A (en) 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
US20020068361A1 (en) 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
US20070026409A1 (en) 2001-08-14 2007-02-01 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
JP2003169699A (ja) 2001-12-10 2003-06-17 Japan Science & Technology Corp 特異的γプロテアーゼ阻害剤のスクリーニング方法
JP2004000060A (ja) 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
JP2006507256A (ja) 2002-09-24 2006-03-02 ザ バーナム インスティチュート Ｅｐｈ受容体活性を調節する新規薬剤
HRP20050461A2 (en) 2002-11-26 2005-08-31 Pharmacia & Upjohn Company Llc Soluble notch-based substrates for gamma secretase and methods and compositions for using same
WO2005048917A2 (fr) 2003-06-06 2005-06-02 Medimmune, Inc. Utilisation du epha4 et de ses modulateurs, pour le diagnostic, le traitement et la prevention du cancer
CN1878865A (zh) 2003-11-10 2006-12-13 财团法人大阪产业振兴机构 无细胞Notch切割分析方法以及药物筛选方法
EP1730279A2 (fr) 2004-02-27 2006-12-13 Oncotherapy Science, Inc. L EphA4 COMME CIBLE TH RAPEUTIQUE DU PCR ET DU PDACa
NZ553273A (en) 2004-09-08 2009-11-27 Univ Melbourne Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling
EP1662259A1 (fr) 2004-11-25 2006-05-31 Cellzome Ag Utilisation des inhibiteurs du récepteur Eph pour le traitement des maladies neurodégénératives
GB0427023D0 (en) 2004-12-09 2005-01-12 Merck Sharp & Dohme Assay method
CN101432022A (zh) 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗-EphA4抗体效应物作用损伤细胞的方法
EP1947193A1 (fr) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé de criblage pour composés antidiabétiques
EP2166110B1 (fr) 2007-06-08 2012-02-22 Eisai R&D Management Co., Ltd. Procédé de criblage employant un nouveau substrat epha4 pour la gamma-secrétase
EP2183598A1 (fr) 2007-07-13 2010-05-12 Elan Pharmaceuticals Inc. Compositions et procédés permettant d'identifier la spécificité de substrat des inhibiteurs de la gamma secrétase
EP2177623A4 (fr) 2007-07-19 2010-12-29 Eisai R&D Man Co Ltd Procede de criblage utilisant c-met, un nouveau substrat pour la gamma-secretase
WO2009017234A1 (fr) 2007-08-01 2009-02-05 Eisai R & D Management Co., Ltd. Procédé de criblage utilisant le nouveau substrat c-ret pour la gamma-sécrétase
EP2031064A1 (fr) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé d'augmentation de titres de protéines
US20090163594A1 (en) 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
US8530181B2 (en) 2007-11-15 2013-09-10 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
US7892769B2 (en) 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2260864A1 (fr) 2009-06-10 2010-12-15 University of Melbourne Applications thérapeutiques
JP2010285413A (ja) 2009-06-10 2010-12-24 Univ Of Melbourne 治療用途
WO2012081502A1 (fr) 2010-12-17 2012-06-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 PROCÉDÉ DE CRIBLAGE INDEXÉ SUR UNE RÉACTION DE CLIVAGE DE L'EphA4 PAR LA GÉLATINASE
US9784751B2 (en) 2011-04-25 2017-10-10 Eisai R&D Management Co., Ltd. Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain
GB201107996D0 (en) 2011-05-13 2011-06-29 Vib Vzw EphA4 is a diease modifier in motor neuron disease
WO2015007222A1 (fr) * 2013-07-17 2015-01-22 The Hong Kong University Of Science And Technology Inhibiteurs d'epha4 en tant qu'agents neuroprotecteurs
EP3177320B1 (fr) * 2014-07-31 2021-01-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Anticorps monoclonaux humains dirigés contre l'epha4 et leur utilisation
PE20181051A1 (es) * 2015-09-08 2018-07-03 Eisai Randd Man Co Ltd Anticuerpo anti-epha4
EP3995582B1 (fr) 2019-07-01 2026-04-22 Eisai R&D Management Co., Ltd. Anticorps anti-epha4

Also Published As

Publication number Publication date
SG11202112433VA (en) 2021-12-30
KR20220027825A (ko) 2022-03-08
LT3995582T (lt) 2026-07-10
NZ783106A (en) 2025-08-29
CL2021003326A1 (es) 2022-07-22
MX2021015298A (es) 2022-01-18
MY207780A (en) 2025-03-18
JP6979147B2 (ja) 2021-12-08
ZA202108836B (en) 2023-04-26
CA3139398A1 (fr) 2021-01-07
TW202248216A (zh) 2022-12-16
PT3995582T (pt) 2026-06-22
TW202342101A (zh) 2023-11-01
RS68231B1 (en) 2026-07-31
TWI866304B (zh) 2024-12-11
US20210002378A1 (en) 2021-01-07
ES3073217T3 (en) 2026-07-09
CN113906050B (zh) 2023-11-21
CO2021016588A2 (es) 2022-04-08
IL287828A (en) 2022-01-01
AR119303A1 (es) 2021-12-09
JPWO2021002312A1 (ja) 2021-09-13
UA129772C2 (uk) 2025-07-30
US11136400B2 (en) 2021-10-05
TWI808882B (zh) 2023-07-11
WO2021002312A1 (fr) 2021-01-07
SMT202600263T1 (it) 2026-07-16
AU2020300205B2 (en) 2026-03-19
TWI779307B (zh) 2022-10-01
KR102953475B1 (ko) 2026-04-16
JP7072114B2 (ja) 2022-05-19
EP3995582B1 (fr) 2026-04-22
FI3995582T3 (fi) 2026-06-15
EP3995582A4 (fr) 2023-01-18
US20210171644A1 (en) 2021-06-10
PH12021553090A1 (en) 2022-07-25
CN113906050A (zh) 2022-01-07
TW202115116A (zh) 2021-04-16
MA56466B1 (fr) 2026-07-31
BR112021025161A2 (pt) 2022-01-25
US10947313B2 (en) 2021-03-16
PE20220570A1 (es) 2022-04-20
JOP20210333A1 (ar) 2021-12-14
JP2022031271A (ja) 2022-02-18
AU2020300205A1 (en) 2022-01-20
EP3995582A1 (fr) 2022-05-11
CN117398459A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA52366A (fr) Anticorps anti-tl1a optimisés
EP3883970A4 (fr) Anticorps anti-b7-h3
MA52742A (fr) Anticorps bispécifiques dll3-cd3
EP3836960A4 (fr) Anticorps cd47 thérapeutiques
MA52212A (fr) Anticorps multivalent
MA49034A (fr) Anticorps anti-lag3
MA47694A (fr) Anticorps anti-tigit
MA55600A (fr) Anticorps anti-ige
MA47268A (fr) Anticorps anti-gpc3
MA52152A (fr) Anticorps
EP3752536A4 (fr) Anticorps anti-her2
EP3995582A4 (fr) Anticorps anti-epha4
EP4081547A4 (fr) Nouveaux anticorps anti-fgfr2b
EP3831851A4 (fr) Anticorps anti-btla
EP3617231A4 (fr) Anticorps anti-gpc-1
EP4271712A4 (fr) Anticorps anti-hvem
MA51134A (fr) Anticorps anti-alpha-synucléine
MA55705A (fr) Anticorps bispécifiques
MA51135A (fr) Anticorps anti-alpha-synucléine
EP4169952A4 (fr) Anticorps anti-trop2
EP3852779A4 (fr) Anticorps anti-klrg1
MA50654A (fr) Anticorps anti-pacap